Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 55 | 2023 | 115 | 10.580 |
Why?
|
| Graft vs Host Disease | 23 | 2023 | 55 | 4.180 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2023 | 50 | 2.850 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 35 | 1.640 |
Why?
|
| Transplantation Conditioning | 23 | 2023 | 41 | 1.410 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2022 | 33 | 0.930 |
Why?
|
| Transplantation, Homologous | 17 | 2023 | 286 | 0.900 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 19 | 0.810 |
Why?
|
| Humans | 67 | 2023 | 28462 | 0.770 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 13 | 0.760 |
Why?
|
| Hodgkin Disease | 4 | 2021 | 18 | 0.700 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 37 | 0.690 |
Why?
|
| Recurrence | 13 | 2023 | 320 | 0.650 |
Why?
|
| Eye Diseases | 4 | 2019 | 7 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 244 | 0.620 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 206 | 0.620 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 4 | 0.610 |
Why?
|
| Retrospective Studies | 24 | 2023 | 3612 | 0.570 |
Why?
|
| Cyclophosphamide | 8 | 2023 | 49 | 0.520 |
Why?
|
| Middle Aged | 27 | 2023 | 9306 | 0.510 |
Why?
|
| Salvage Therapy | 3 | 2021 | 36 | 0.500 |
Why?
|
| Adult | 27 | 2023 | 8152 | 0.500 |
Why?
|
| Transplantation, Autologous | 8 | 2022 | 168 | 0.440 |
Why?
|
| Prognosis | 12 | 2023 | 824 | 0.420 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 63 | 0.400 |
Why?
|
| Disease-Free Survival | 10 | 2022 | 177 | 0.400 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 21 | 0.390 |
Why?
|
| Calcineurin Inhibitors | 5 | 2023 | 16 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 15 | 0.350 |
Why?
|
| Adolescent | 12 | 2023 | 2324 | 0.350 |
Why?
|
| Male | 23 | 2022 | 15367 | 0.340 |
Why?
|
| Aged | 20 | 2023 | 9339 | 0.340 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 9 | 0.330 |
Why?
|
| Young Adult | 12 | 2021 | 2100 | 0.310 |
Why?
|
| Allografts | 5 | 2021 | 222 | 0.300 |
Why?
|
| Female | 22 | 2023 | 15793 | 0.280 |
Why?
|
| Survival Rate | 8 | 2021 | 356 | 0.280 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 1 | 0.260 |
Why?
|
| Splenic Diseases | 1 | 2006 | 3 | 0.260 |
Why?
|
| Rituximab | 3 | 2023 | 50 | 0.260 |
Why?
|
| Chromosome Aberrations | 3 | 2021 | 14 | 0.250 |
Why?
|
| Melphalan | 5 | 2023 | 6 | 0.230 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 138 | 0.230 |
Why?
|
| Mycoses | 1 | 2023 | 23 | 0.220 |
Why?
|
| Scedosporium | 1 | 2023 | 4 | 0.220 |
Why?
|
| Bacterial Infections | 1 | 2023 | 52 | 0.210 |
Why?
|
| Risk Factors | 5 | 2023 | 2421 | 0.210 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 2 | 0.210 |
Why?
|
| Quality of Life | 4 | 2022 | 660 | 0.210 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 2 | 0.210 |
Why?
|
| POEMS Syndrome | 1 | 2022 | 1 | 0.200 |
Why?
|
| Remission Induction | 5 | 2022 | 90 | 0.200 |
Why?
|
| Unrelated Donors | 4 | 2023 | 5 | 0.200 |
Why?
|
| Vidarabine | 4 | 2023 | 9 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2019 | 47 | 0.200 |
Why?
|
| Autografts | 2 | 2019 | 31 | 0.190 |
Why?
|
| Bone Marrow | 4 | 2023 | 81 | 0.190 |
Why?
|
| Hypogonadism | 1 | 2021 | 7 | 0.190 |
Why?
|
| Infertility | 1 | 2021 | 8 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 19 | 0.190 |
Why?
|
| Busulfan | 4 | 2023 | 4 | 0.190 |
Why?
|
| Heart Failure | 1 | 2023 | 175 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 4 | 2023 | 26 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 15 | 0.190 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 4 | 0.180 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 6 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 17 | 0.180 |
Why?
|
| Siblings | 4 | 2022 | 15 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 35 | 0.180 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 2 | 0.180 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 43 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 10 | 0.180 |
Why?
|
| Return to Work | 1 | 2021 | 65 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 4 | 0.170 |
Why?
|
| Calcineurin | 1 | 2020 | 9 | 0.170 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 3 | 0.170 |
Why?
|
| Infliximab | 1 | 2020 | 17 | 0.170 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 373 | 0.170 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 1 | 0.170 |
Why?
|
| Survival Analysis | 4 | 2021 | 267 | 0.160 |
Why?
|
| Steroids | 1 | 2019 | 25 | 0.160 |
Why?
|
| Typhlitis | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mucositis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Neoplasms | 1 | 2022 | 242 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 192 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 4 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2019 | 46 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 35 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 91 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 95 | 0.150 |
Why?
|
| Acute Disease | 3 | 2023 | 208 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 260 | 0.150 |
Why?
|
| Incidence | 4 | 2023 | 779 | 0.150 |
Why?
|
| Lymphoma | 1 | 2017 | 38 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 9 | 0.140 |
Why?
|
| Cachexia | 1 | 2017 | 13 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2023 | 692 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2023 | 442 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 612 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3619 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4904 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1868 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2012 | 24 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 49 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 676 | 0.100 |
Why?
|
| Melanoma | 1 | 2012 | 60 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 80 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 190 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2022 | 1948 | 0.090 |
Why?
|
| Vincristine | 2 | 2023 | 21 | 0.090 |
Why?
|
| Tacrolimus | 2 | 2021 | 15 | 0.090 |
Why?
|
| Prednisone | 2 | 2023 | 65 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2023 | 55 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2020 | 66 | 0.080 |
Why?
|
| Mutation | 2 | 2023 | 349 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 179 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2020 | 163 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 11 | 0.080 |
Why?
|
| Etoposide | 2 | 2020 | 26 | 0.080 |
Why?
|
| Registries | 2 | 2020 | 191 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 334 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2020 | 1810 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 502 | 0.070 |
Why?
|
| Pain | 2 | 2021 | 406 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 352 | 0.070 |
Why?
|
| Disease Progression | 2 | 2022 | 719 | 0.070 |
Why?
|
| Child | 2 | 2021 | 1423 | 0.070 |
Why?
|
| Splenomegaly | 1 | 2006 | 6 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Splenectomy | 1 | 2006 | 7 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2006 | 8 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 58 | 0.060 |
Why?
|
| United States | 2 | 2023 | 2185 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 36 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 372 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 21 | 0.050 |
Why?
|
| Toes | 1 | 2023 | 6 | 0.050 |
Why?
|
| Voriconazole | 1 | 2023 | 12 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 44 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 79 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2022 | 11 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 22 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2022 | 13 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 3 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 8 | 0.050 |
Why?
|
| Survivors | 1 | 2021 | 72 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 51 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 13 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 78 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 1 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 53 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 65 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 63 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 52 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 50 | 0.040 |
Why?
|
| Blood Donors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 13 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 77 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 5 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 67 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 793 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 152 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 16 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2017 | 14 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 20 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 29 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2017 | 35 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 185 | 0.030 |
Why?
|
| Methotrexate | 1 | 2017 | 36 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 141 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 288 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 601 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 128 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 349 | 0.020 |
Why?
|